The Modulatory Role of Internet MBCT on Extracellular Vesicles and Distress in Cancer Patients - Study Protocol

Cancer Clinical Trial

— MINDGAP  

Official title:

The Modulatory Role of Internet-supported Mindfulness-based Cognitive Therapy on Extracellular Vesicles and Psychological Distress in People Who Have Had Cancer: A Study Protocol for a Two-armed Randomized Controlled Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04727593
• Other study ID #: IPO/PI134b
• Status: Recruiting
• Phase: N/A
• Start date: September 3, 2021
• Est. completion date: March 31, 2024

Study information

• Verified date: September 2023
• Source: Instituto Portugues de Oncologia, Francisco Gentil, Porto
• Contact: Eunice Silva, PhD
• Phone: 00351 961761035
• Email: esilva[@]ipoporto.min-saude.pt
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Mindfulness-based interventions (MBIs), such as mindfulness-based stress reduction (MBSR), mindfulness-based cognitive therapy (MBCT), mindfulness-based cancer recovery (MBCR), have been showing promising results in different health-related and psychosocial outcomes in the context of cancer. More recently, the possibility of delivering MBIs using technological tools and resources, such as internet and applications, has been receiving much attention, also accompanied by promising findings. However, few randomized controlled studies have been conducted and published to date. Moreover, few studies have addressed the long-term stability and trajectory of gains across time. Also, even though prior evidence had suggested that face-to-face MBIs might modulate several biological markers (e.g., pro-inflammatory gene expression and inflammatory signaling; telomere length), as far as we know, no previous study addressed the impact of online MBIs on biological indices, especially on extracellular vesicles (EVs).

As primary objective, this study aims to investigate the effects of an internet-based MBCT intervention (vs. Treatment as Usual - TAU) on EVs (objective measure), as well as on psychological distress (subjective measure), considering a sample of distressed people with history of breast, prostate, and colorectal cancer.

As secondary objective, this study aims to investigate the effects of this same intervention on psychosocial outcomes, including quality of life, fear of cancer recurrence, emotion suppression, mindfulness, sleep quality, posttraumatic growth, health-related behaviours (physical activity; smoking habits), and perceived social support. The biological secondary outcomes studied will be: inflammatory response genes interleukins (ILs, IL-1, IL-6, IL-8, IL-10), interferon gamma (IFN-γ), tumour necrosis factor (TNF), and c-reactive protein (CRP); telomerase activity; antigens related to cancer (cancer antigen - CA 15-3; prostate-specific antigen - PSA; carcinoembryonic antigen - CEA); other health-related markers (adrenocorticotropic hormone - ACTH; erythrocytes number; hemoglobin glycosylated).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 111
• Est. completion date: March 31, 2024
• Est. primary completion date: March 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Diagnosis of breast, prostate, or colorectal cancer;

• Cancer stage I - III;

• Primary cancer treatments completed between 3 months and 5 years (participants with ongoing adjuvant hormonal therapies will be included);

• Age between 18 and 65 years;

• Experiencing significant distress on the Distress Thermometer (DT = 4)

• Willingness to accept randomization to one of the two study conditions and to attend the study for its duration;

• Ability to speak, read, and write in Portuguese and literacy to complete autonomously the self-report measures;

• Sufficient digital literacy with access to a device (e.g., smartphone; tablet; computer) with camera, microphone, and internet.

Exclusion Criteria:

• Concurrent diagnosis of severe psychiatric condition(s) (e.g., psychosis; substance abuse; bipolar disorder; suicidal ideation);

• Concurrent diagnosis of autoimmune disorder;

• Current use of antipsychotics;

• Current use of anti-inflammatory medication (corticotherapy);

• Undergoing trastuzumab therapy;

• Participation in a structured mindfulness program (e.g., MBCT; MBSR; Mindfulness-Based Cancer Recovery - MBCR) program in the past five years;

• Currently attending psychological consultation;

• Being pregnant or breastfeeding.

Related Conditions & MeSH terms

• Cancer

Intervention

Behavioral:
• Mindfulness Based Cognitive Therapy (MBCT)
Experimental group: MBCT is program developed by Zindel Segal, Mark Williams, and John Teasdale , based on Jon Kabat-Zinn's Mindfulness-based Stress Reduction (MBSR) program. Participants learn to acknowledge their unhelpful thoughts and feelings, allowing the mind to move from an automatic and spiraling thought pattern to a more conscious emotional processing. Mindfulness practices include breath awareness, sitting and walking meditations, and mindful yoga. In this study, the following MBCT structure will be followed: group setting of 12 participants (maximum); 8 online weekly meetings of 2 hours via a videoconference platform (e.g., Cisco Webex), each one mediated by a trained mindfulness instructor(s); daily home practice of the learned skills; 2 hours of retreat after the fifth week; 6 months of home practice; 4 monthly consolidation sessions of 90 minutes each.

Other:
• Treatment as Usual
In this case, participants will follow the usual institutional intervention protocol for medical follow-up and identification, referral, and intervention for people with significant distress difficulties. Regarding pharmacological intervention, medication intake will be monitored during the study and changes will be registered. The engagement in non-pharmacological interventions such as psychological and psychosocial interventions will also be monitored.

Locations

Country	Name	City	State
Portugal	Instituto Português de Oncologia do Porto Francisco Gentil, EPE	Porto

Sponsors (6)

Lead Sponsor	Collaborator
Instituto Portugues de Oncologia, Francisco Gentil, Porto	European Commission, Linnaeus University, University of Coimbra, University of Oulu, VTT Technical Research Centre, Finland

Country where clinical trial is conducted

Portugal, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change on Extracellular Vesicles	Isolated by ultracentrifugation with sucrose cushion. The collected EVs will be quantified by Nanoparticle tracking analysis (Nanosight Ltd.), and data will be measured in particles per milliliter (mL).	T1 - before intervention; 8 weeks after T1; 24 weeks after T1
Primary	Change on Distress	Measured with Depression Anxiety Stress Scales-21 - DASS-21, a self-report and public domain questionnaire that evaluates negative affective states. It is composed of 21 items, 7 focused on depression, 7 on anxiety, and 7 on stress. Each item is rated on a 4-point Likert-type scale, wherein in 0 represents "did not apply to me at all" and 3 represents "applied to me very much or most of the time". The score for each subscale ranges between 0 and 21. In the current study, a total score will be computed by summing all items, with higher scores being indicative of higher self-reported psychological distress.	T1- before intervention; T2 - 4 weeks after baseline; T3 - 8 weeks after baseline; T4 - 24 weeks after baseline; T5 - 52 weeks after baseline
Secondary	Change on Cancer antigen 15-3 (CA 15-3)	Using an immunoassay analyser (units/mL).	T1- before intervention; T3 - 8 weeks after baseline; T4 - 24 weeks after baseline
Secondary	Change on Prostate-specific antigen (PSA)	Using an immunoassay analyser (ng/mL).	T1- before intervention; T3 - 8 weeks after baseline; T4 - 24 weeks after baseline
Secondary	Change on Carcinoembryonic Antigen (CEA).	Using an immunoassay analyser (ng/mL).	T1- before intervention; T3 - 8 weeks after baseline; T4 - 24 weeks after baseline
Secondary	Change on Adrenocorticotropic Hormone (ACTH).	Using an immunoassay analyser (pg/mL).	T1- before intervention; T3 - 8 weeks after baseline; T4 - 24 weeks after baseline
Secondary	Transcript inflammatory response genes (Interleukins, ILs, IL-1, IL-6, IL-8, IL-10, IFN? and TNF).	Assessed by quantitative RT-PCR (TaqMan™ Gene Expression Assays).	T1- before intervention; T3 - 8 weeks after baseline; T4 - 24 weeks after baseline
Secondary	Change on Analytic biomarkers (Erythrocyte number).	This indicator assesses erythrocytes number (million/mm3) from blood samples (Sysmex XN).	T1- before intervention; T3 - 8 weeks after baseline; T4 - 24 weeks after baseline
Secondary	Change on Analytic biomarkers (PCR number).	This indicator assesses PCR (mg/L) from blood samples.	T1- before intervention; T3 - 8 weeks after baseline; T4 - 24 weeks after baseline
Secondary	Change on Analytic biomarkers (telomerase activity).	This indicator assesses telomerase activity (units) from blood samples.	T1- before intervention; T3 - 8 weeks after baseline; T4 - 24 weeks after baseline
Secondary	Change on Analytic biomarkers (hemoglobin glycosylated).	This indicator assesses High Performance Liquid Chromatography - HPLC, (mmol/mol) from blood samples.	T1- before intervention; T3 - 8 weeks after baseline; T4 - 24 weeks after baseline
Secondary	Change on Global distress	Measured with Clinical Outcome Routine Evaluation - Outcome Measure, (CORE-OM) , a self-report measure of global distress (GD), comprising 34 items and four domains: subjective well-being, commonly experienced problems or symptoms, social/life functioning, and risk to self and others. The measure is scored on a 5-point scale ranging from 0 ('not at all') to 4 ('all the time'). The measure is suitable for use across a wide range of settings, it has been validated in different adult population with mental health problems, and it is sensitive to change.	T0 - Screening; T2 - 4 weeks after baseline; T3 - 8 weeks after baseline; T4 - 24 weeks after baseline; T5 - 52 weeks after baseline
Secondary	Change on quality of life	Measured by World Health Organization Quality of Life - Bref - WHOQOL-Bref, a questionnaire suitable for epidemiological and clinical trials, which assesses quality of life as proposed by WHO. It is composed of 26 items distributed in one general facet and four domains (physical health, psychological, social relationships, and environment). Each item is rated on a 5-point Likert-type scale with higher scores being indicative of better self-reported quality of life (scoring procedures are available here: https://www.who.int/mental_health/media/en/76.pdf).	T1 - Baseline; T3 - 8 weeks after baseline; T4 - 24 weeks after baseline; T5 - 52 weeks after baseline
Secondary	Change on fear of cancer recurrence	Measured by a 7-item Fear of Cancer Recurrence - FCR-7 (PT version not yet available), a 7-item scale assessing fear of cancer recurrence in a 5-point Likert scale ranging from 1 (not at all) to 5 (all the time). It had demonstrated good psychometric properties. We will translate, adapt and validate this measure, following the usual procedures to adapt psychological measures.	T1 - Baseline; T3 - 8 weeks after baseline; T4 - 24 weeks after baseline; T5 - 52 weeks after baseline
Secondary	Change on satisfaction perceived social support	Satisfaction with Social Support Scale - SSSS, a 15-item scale assessing social support satisfaction discriminating four dimensions: satisfaction with friends/friendships, intimacy, satisfaction with family and social activities.	T1 - Baseline; T3 - 8 weeks after baseline; T4 - 24 weeks after baseline; T5 - 52 weeks after baseline
Secondary	Change on emotional suppression	Emotion Regulation Questionnaire - ERQ) , - Only the subscale of emotion suppression composed of 4-items will be used. The items are rated in 7-point Likert-type scale ranging from 1 (strongly disagree) to 7 (strongly agree).	T1 - Baseline; T3 - 8 weeks after baseline; T4 - 24 weeks after baseline; T5 - 52 weeks after baseline
Secondary	Change on mindfulness abilities	Measured by Mindfulness Five Facet Mindfulness Questionnaire - FFMQ, a 39 items questionnaire that assess mindfulness and self-awareness states in everyday life, which are organized in five different facets/subscales: observing, describing, acting with awareness, nonreactivity to inner experience, and nonjudging of inner experience. Each item is rated on a 5-point Likert-type scale ranging from 1 (never or very rarely true) and 5 (very often or always true).	T1 Baseline; T2 - 4 weeks after baseline; T3 - 8 weeks after baseline; T4 - 24 weeks after baseline; T5 - 52 weeks after baseline
Secondary	Change Interview	This interview assesses the psychotherapeutic changes perceived by participants after psychological intervention. The interview questions explore the changes that a person has noticed since therapy began, what the person attributes these changes to, and helpful and unhelpful aspects of therapy, in a qualitative way.	T3 - 8 weeks after baseline
Secondary	Change on smoking dependency	Measured with Fageström Test for Nicotine Dependence - FTND. This instrument assesses nicotine dependency with 6 items (rated from 0 to 2 or 3). The total score range is 1-10, with higher values meaning higher nicotine dependency.	T1 - Baseline; T3 - 8 weeks after baseline; T4 - 24 weeks after baseline; T5 - 52 weeks after baseline
Secondary	Change on physical activity	Measured with International Physical Activity Questionnaire - Short Form - IPAQ-SF. This instrument assesses physical activity in 7 items, with higher scores meaning higher level of physical activity.	T1 - Baseline; T3 - 8 weeks after baseline; T4 - 24 weeks after baseline; T5 - 52 weeks after baseline
Secondary	Change on sleep quality	Measured with Basic Scale on Insomnia complaints and Quality of Sleep - BaSIQS - This is a self-report measure that focus on evaluating sleep quality, as well as problems to fall asleep and maintain sleep. It encompasses 7 items rated in a 5-point Likert-type and the total score ranges between 0 and 28, with highest values indicating poor sleep quality. Satisfactory psychometric properties were reported in the original study with Portuguese higher education students, but also on community and clinical samples	T1 - Baseline; T3 - 8 weeks after baseline; T4 - 24 weeks after baseline; T5 - 52 weeks after baseline
Secondary	Change on posttraumatic growth	Measured with Posttraumatic Growth Inventory - PTGI, which is a self-report questionnaire that evaluates positive psychological change in people experiencing traumatic events. It includes 21 items and each item is rated on a 6-point Likert-type scale ranging from 0 ("I did not experience this change as a result of my crisis") to 5 ("I experienced this change to a very great degree as a result of my crisis"). Total score ranges between 0 and 105, with higher values being indicative of a greater degree of posttraumatic growth.	T1 - Baseline; T3 - 8 weeks after baseline; T4 - 24 weeks after baseline; T5 - 52 weeks after baseline

External Links

•   MindGAP project website